ERBB2 and neoplasm: Interestingly, simultaneous injection of an oncolytic adenovirus and a helper-dependent adenovirus expressing a PD-L1 blocking mini-antibody in combination with HER2 targeting CAR T cells, produced superior anti-tumour efficacy in murine models of solid tumours compared to using these therapeutics as single agents[114].